The primary cause of mortality in patients of coronavirus disease 2019 (COVID-19) is the
cytokine storm and not directly due to the severe acute respiratory syndrome coronavirus 2 …

Various agents are currently under evaluation as potential treatments in the fight against
coronavirus disease 2019 (COVID-19). Plasma from patients that have overcome COVID-19 …

Objectives Being COVID-19 convalescent plasma (CCP) a therapeutic option that can have
a potential impact on the normalization of immunological parameters of COVID-19 affected …

Abstract Objectives General: To assess the safety, efficacy and dose response of
convalescent plasma (CP) transfusion in severe COVID-19 patients Specific: a. To identify …

Abstract Introduction South America is one of the regions most affected by the COVID19
pandemic. Specific and affordable treatments are needed to treat SARSCoV2 infection …

Introductions Results with convalescent plasma therapy in coronavirus disease 2019
(COVID-19) have been contradictory. Timing seems to be an important factor for COVID-19 …

Background and Objectives: On 24 March 2020, the United States Food and Drug
Administration (FDA) announced the approval of convalescent plasma therapy for critically ill …

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged …

Objective This study aimed to investigate the efficacy and safety of convalescent plasma
(CP) transfusion in a group of high-risk COVID-19 patients. Methods This prospective study …

Background and objectives The use of COVID-19 convalescent plasma (CCP) has been
approved by the FDA. We assessed the outcome of patients with moderate and severe …